nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ERBB4—gallbladder cancer	0.409	0.479	CbGaD
Afatinib—ERBB2—gallbladder cancer	0.302	0.354	CbGaD
Afatinib—EGFR—gallbladder cancer	0.143	0.167	CbGaD
Afatinib—ERBB2—gall bladder—gallbladder cancer	0.00347	0.149	CbGeAlD
Afatinib—Vandetanib—ERBB3—gallbladder cancer	0.00202	0.354	CrCbGaD
Afatinib—Gefitinib—ERBB3—gallbladder cancer	0.00192	0.336	CrCbGaD
Afatinib—ERBB4—epithelium—gallbladder cancer	0.00179	0.0771	CbGeAlD
Afatinib—ERBB2—epithelium—gallbladder cancer	0.00179	0.0771	CbGeAlD
Afatinib—ERBB2—pancreas—gallbladder cancer	0.0016	0.0687	CbGeAlD
Afatinib—IRAK1—pancreas—gallbladder cancer	0.0012	0.0514	CbGeAlD
Afatinib—BLK—lymph node—gallbladder cancer	0.00114	0.0489	CbGeAlD
Afatinib—PHKG2—liver—gallbladder cancer	0.00113	0.0486	CbGeAlD
Afatinib—ERBB2—liver—gallbladder cancer	0.00102	0.0437	CbGeAlD
Afatinib—DYRK1A—liver—gallbladder cancer	0.000979	0.0421	CbGeAlD
Afatinib—Vandetanib—EGFR—gallbladder cancer	0.000904	0.159	CrCbGaD
Afatinib—PHKG2—lymph node—gallbladder cancer	0.000867	0.0373	CbGeAlD
Afatinib—EGFR—liver—gallbladder cancer	0.000862	0.0371	CbGeAlD
Afatinib—Gefitinib—EGFR—gallbladder cancer	0.000859	0.151	CrCbGaD
Afatinib—ERBB2—lymph node—gallbladder cancer	0.00078	0.0335	CbGeAlD
Afatinib—IRAK1—liver—gallbladder cancer	0.000761	0.0327	CbGeAlD
Afatinib—DYRK1A—lymph node—gallbladder cancer	0.00075	0.0323	CbGeAlD
Afatinib—LCK—liver—gallbladder cancer	0.000742	0.0319	CbGeAlD
Afatinib—ABL1—pancreas—gallbladder cancer	0.00067	0.0288	CbGeAlD
Afatinib—EGFR—lymph node—gallbladder cancer	0.000661	0.0284	CbGeAlD
Afatinib—IRAK1—lymph node—gallbladder cancer	0.000583	0.0251	CbGeAlD
Afatinib—LCK—lymph node—gallbladder cancer	0.000569	0.0244	CbGeAlD
Afatinib—ABL1—liver—gallbladder cancer	0.000426	0.0183	CbGeAlD
Afatinib—ABL1—lymph node—gallbladder cancer	0.000327	0.014	CbGeAlD
Afatinib—ABCG2—liver—gallbladder cancer	0.000269	0.0115	CbGeAlD
Afatinib—ABCB1—epithelium—gallbladder cancer	0.000234	0.01	CbGeAlD
Afatinib—ABCB1—pancreas—gallbladder cancer	0.000208	0.00895	CbGeAlD
Afatinib—ABCG2—lymph node—gallbladder cancer	0.000206	0.00886	CbGeAlD
Afatinib—ABCB1—liver—gallbladder cancer	0.000132	0.0057	CbGeAlD
Afatinib—ABCB1—lymph node—gallbladder cancer	0.000102	0.00437	CbGeAlD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	3.43e-05	0.000292	CbGpPWpGaD
Afatinib—LCK—Downstream signaling of activated FGFR—HRAS—gallbladder cancer	3.43e-05	0.000292	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—NRAS—gallbladder cancer	3.4e-05	0.00029	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—TP53—gallbladder cancer	3.38e-05	0.000288	CbGpPWpGaD
Afatinib—EGFR—B Cell Activation—KRAS—gallbladder cancer	3.37e-05	0.000287	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB4—HRAS—gallbladder cancer	3.37e-05	0.000287	CbGpPWpGaD
Afatinib—PHKG2—Disease—EGFR—gallbladder cancer	3.36e-05	0.000286	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—NRAS—gallbladder cancer	3.35e-05	0.000285	CbGpPWpGaD
Afatinib—EGFR—Downstream signal transduction—HRAS—gallbladder cancer	3.34e-05	0.000285	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—BCL2—gallbladder cancer	3.33e-05	0.000283	CbGpPWpGaD
Afatinib—EGFR—EGF/EGFR Signaling Pathway—HRAS—gallbladder cancer	3.32e-05	0.000283	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR—HRAS—gallbladder cancer	3.32e-05	0.000283	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—ERBB3—gallbladder cancer	3.32e-05	0.000283	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—KRAS—gallbladder cancer	3.32e-05	0.000282	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—ERBB3—gallbladder cancer	3.31e-05	0.000282	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB2—HRAS—gallbladder cancer	3.31e-05	0.000282	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—EGFR—gallbladder cancer	3.29e-05	0.00028	CbGpPWpGaD
Afatinib—EGFR—DAP12 signaling—HRAS—gallbladder cancer	3.29e-05	0.00028	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—NRAS—gallbladder cancer	3.27e-05	0.000278	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—KRAS—gallbladder cancer	3.25e-05	0.000277	CbGpPWpGaD
Afatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—gallbladder cancer	3.24e-05	0.000276	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—ERBB2—gallbladder cancer	3.23e-05	0.000275	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—KRAS—gallbladder cancer	3.23e-05	0.000275	CbGpPWpGaD
Afatinib—LCK—Downstream signal transduction—HRAS—gallbladder cancer	3.22e-05	0.000274	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—NRAS—gallbladder cancer	3.22e-05	0.000274	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—HRAS—gallbladder cancer	3.21e-05	0.000273	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR—HRAS—gallbladder cancer	3.2e-05	0.000273	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—ERBB3—gallbladder cancer	3.19e-05	0.000272	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB2—HRAS—gallbladder cancer	3.19e-05	0.000272	CbGpPWpGaD
Afatinib—PHKG2—Disease—KRAS—gallbladder cancer	3.18e-05	0.000271	CbGpPWpGaD
Afatinib—LCK—DAP12 signaling—HRAS—gallbladder cancer	3.17e-05	0.00027	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—HRAS—gallbladder cancer	3.16e-05	0.000269	CbGpPWpGaD
Afatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—HRAS—gallbladder cancer	3.13e-05	0.000266	CbGpPWpGaD
Afatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—gallbladder cancer	3.12e-05	0.000266	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—KRAS—gallbladder cancer	3.11e-05	0.000265	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—ERBB4—gallbladder cancer	3.11e-05	0.000265	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—EGFR—gallbladder cancer	3.1e-05	0.000264	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—HRAS—gallbladder cancer	3.1e-05	0.000264	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR in disease—HRAS—gallbladder cancer	3.1e-05	0.000264	CbGpPWpGaD
Afatinib—EGFR—Fc epsilon receptor (FCERI) signaling—HRAS—gallbladder cancer	3.1e-05	0.000264	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—NRAS—gallbladder cancer	3.1e-05	0.000264	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR—HRAS—gallbladder cancer	3.07e-05	0.000261	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—NRAS—gallbladder cancer	3.05e-05	0.00026	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—EGFR—gallbladder cancer	3.05e-05	0.00026	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	3.05e-05	0.00026	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR in Cancer—HRAS—gallbladder cancer	3.04e-05	0.000259	CbGpPWpGaD
Afatinib—EGFR—Signaling by PDGF—HRAS—gallbladder cancer	3.03e-05	0.000258	CbGpPWpGaD
Afatinib—IRAK1—Immune System—ERBB3—gallbladder cancer	3e-05	0.000256	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—HRAS—gallbladder cancer	2.98e-05	0.000254	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—HRAS—gallbladder cancer	2.98e-05	0.000254	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—HRAS—gallbladder cancer	2.98e-05	0.000254	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—EGFR—gallbladder cancer	2.98e-05	0.000254	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—HRAS—gallbladder cancer	2.96e-05	0.000252	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—EGFR—gallbladder cancer	2.93e-05	0.00025	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—HRAS—gallbladder cancer	2.93e-05	0.00025	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—KRAS—gallbladder cancer	2.93e-05	0.000249	CbGpPWpGaD
Afatinib—EGFR—Focal Adhesion—HRAS—gallbladder cancer	2.93e-05	0.000249	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—HRAS—gallbladder cancer	2.92e-05	0.000249	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—KRAS—gallbladder cancer	2.88e-05	0.000246	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—NRAS—gallbladder cancer	2.88e-05	0.000246	CbGpPWpGaD
Afatinib—EGFR—B Cell Activation—HRAS—gallbladder cancer	2.87e-05	0.000244	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—ERBB2—gallbladder cancer	2.86e-05	0.000244	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—NRAS—gallbladder cancer	2.83e-05	0.000241	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—EGFR—gallbladder cancer	2.82e-05	0.00024	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—HRAS—gallbladder cancer	2.82e-05	0.00024	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—KRAS—gallbladder cancer	2.81e-05	0.00024	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—EGFR—gallbladder cancer	2.78e-05	0.000237	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—NRAS—gallbladder cancer	2.78e-05	0.000237	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—KRAS—gallbladder cancer	2.77e-05	0.000236	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—HRAS—gallbladder cancer	2.76e-05	0.000235	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—gallbladder cancer	2.74e-05	0.000234	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—gallbladder cancer	2.72e-05	0.000232	CbGpPWpGaD
Afatinib—ABL1—Immune System—ERBB4—gallbladder cancer	2.72e-05	0.000232	CbGpPWpGaD
Afatinib—PHKG2—Disease—HRAS—gallbladder cancer	2.7e-05	0.00023	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—ERBB3—gallbladder cancer	2.69e-05	0.000229	CbGpPWpGaD
Afatinib—ERBB2—Immune System—BCL2—gallbladder cancer	2.68e-05	0.000228	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—KRAS—gallbladder cancer	2.66e-05	0.000227	CbGpPWpGaD
Afatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—gallbladder cancer	2.65e-05	0.000226	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—ERBB3—gallbladder cancer	2.65e-05	0.000225	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—HRAS—gallbladder cancer	2.64e-05	0.000225	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—gallbladder cancer	2.64e-05	0.000225	CbGpPWpGaD
Afatinib—ERBB4—Immune System—BCL2—gallbladder cancer	2.64e-05	0.000225	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—KRAS—gallbladder cancer	2.63e-05	0.000224	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—NRAS—gallbladder cancer	2.61e-05	0.000222	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—BCL2—gallbladder cancer	2.6e-05	0.000222	CbGpPWpGaD
Afatinib—ERBB4—Immune System—ERBB2—gallbladder cancer	2.57e-05	0.000219	CbGpPWpGaD
Afatinib—BLK—Immune System—BCL2—gallbladder cancer	2.54e-05	0.000216	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—EGFR—gallbladder cancer	2.53e-05	0.000216	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—ERBB2—gallbladder cancer	2.53e-05	0.000216	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—HRAS—gallbladder cancer	2.49e-05	0.000212	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—KRAS—gallbladder cancer	2.48e-05	0.000211	CbGpPWpGaD
Afatinib—BLK—Immune System—ERBB2—gallbladder cancer	2.47e-05	0.00021	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—NRAS—gallbladder cancer	2.46e-05	0.00021	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—HRAS—gallbladder cancer	2.45e-05	0.000209	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—ERBB2—gallbladder cancer	2.45e-05	0.000209	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—KRAS—gallbladder cancer	2.43e-05	0.000207	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—KRAS—gallbladder cancer	2.39e-05	0.000204	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—HRAS—gallbladder cancer	2.39e-05	0.000204	CbGpPWpGaD
Afatinib—ERBB4—Disease—ERBB2—gallbladder cancer	2.37e-05	0.000202	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—HRAS—gallbladder cancer	2.35e-05	0.000201	CbGpPWpGaD
Afatinib—ABL1—Immune System—ERBB3—gallbladder cancer	2.35e-05	0.0002	CbGpPWpGaD
Afatinib—EGFR—Immune System—ERBB4—gallbladder cancer	2.32e-05	0.000198	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—HRAS—gallbladder cancer	2.26e-05	0.000193	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—KRAS—gallbladder cancer	2.25e-05	0.000191	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ERBB4—gallbladder cancer	2.25e-05	0.000191	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—EGFR—gallbladder cancer	2.24e-05	0.000191	CbGpPWpGaD
Afatinib—LCK—Immune System—ERBB4—gallbladder cancer	2.24e-05	0.000191	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—HRAS—gallbladder cancer	2.23e-05	0.00019	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—BCL2—gallbladder cancer	2.23e-05	0.00019	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—NRAS—gallbladder cancer	2.18e-05	0.000186	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—ERBB2—gallbladder cancer	2.16e-05	0.000184	CbGpPWpGaD
Afatinib—EGFR—Disease—ERBB4—gallbladder cancer	2.14e-05	0.000183	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—BCL2—gallbladder cancer	2.14e-05	0.000183	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—NRAS—gallbladder cancer	2.14e-05	0.000182	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—KRAS—gallbladder cancer	2.12e-05	0.00018	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—HRAS—gallbladder cancer	2.11e-05	0.00018	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—ERBB2—gallbladder cancer	2.08e-05	0.000177	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—ERBB2—gallbladder cancer	2.08e-05	0.000177	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—HRAS—gallbladder cancer	2.07e-05	0.000176	CbGpPWpGaD
Afatinib—LCK—Disease—ERBB4—gallbladder cancer	2.07e-05	0.000176	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—HRAS—gallbladder cancer	2.03e-05	0.000173	CbGpPWpGaD
Afatinib—EGFR—Immune System—ERBB3—gallbladder cancer	2.01e-05	0.000171	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—ERBB2—gallbladder cancer	2e-05	0.00017	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—EGFR—gallbladder cancer	1.99e-05	0.000169	CbGpPWpGaD
Afatinib—ERBB2—Immune System—NRAS—gallbladder cancer	1.98e-05	0.000169	CbGpPWpGaD
Afatinib—ERBB4—Immune System—NRAS—gallbladder cancer	1.95e-05	0.000166	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ERBB3—gallbladder cancer	1.94e-05	0.000165	CbGpPWpGaD
Afatinib—IRAK1—Immune System—BCL2—gallbladder cancer	1.94e-05	0.000165	CbGpPWpGaD
Afatinib—LCK—Immune System—ERBB3—gallbladder cancer	1.94e-05	0.000165	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—NRAS—gallbladder cancer	1.92e-05	0.000164	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—HRAS—gallbladder cancer	1.91e-05	0.000163	CbGpPWpGaD
Afatinib—IRAK1—Immune System—ERBB2—gallbladder cancer	1.88e-05	0.00016	CbGpPWpGaD
Afatinib—BLK—Immune System—NRAS—gallbladder cancer	1.88e-05	0.00016	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—KRAS—gallbladder cancer	1.88e-05	0.00016	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—NRAS—gallbladder cancer	1.86e-05	0.000159	CbGpPWpGaD
Afatinib—EGFR—Disease—ERBB3—gallbladder cancer	1.85e-05	0.000158	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—KRAS—gallbladder cancer	1.84e-05	0.000157	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—gallbladder cancer	1.83e-05	0.000156	CbGpPWpGaD
Afatinib—ERBB2—Disease—NRAS—gallbladder cancer	1.83e-05	0.000156	CbGpPWpGaD
Afatinib—ERBB2—Immune System—EGFR—gallbladder cancer	1.81e-05	0.000154	CbGpPWpGaD
Afatinib—ERBB4—Disease—NRAS—gallbladder cancer	1.8e-05	0.000154	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—HRAS—gallbladder cancer	1.8e-05	0.000153	CbGpPWpGaD
Afatinib—LCK—Disease—ERBB3—gallbladder cancer	1.79e-05	0.000152	CbGpPWpGaD
Afatinib—ERBB4—Immune System—EGFR—gallbladder cancer	1.78e-05	0.000151	CbGpPWpGaD
Afatinib—LCK—Hemostasis—NRAS—gallbladder cancer	1.76e-05	0.00015	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—EGFR—gallbladder cancer	1.75e-05	0.000149	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	1.73e-05	0.000147	CbGpPWpGaD
Afatinib—BLK—Immune System—EGFR—gallbladder cancer	1.71e-05	0.000146	CbGpPWpGaD
Afatinib—ERBB2—Immune System—KRAS—gallbladder cancer	1.71e-05	0.000145	CbGpPWpGaD
Afatinib—ERBB4—Immune System—KRAS—gallbladder cancer	1.68e-05	0.000143	CbGpPWpGaD
Afatinib—ERBB2—Disease—EGFR—gallbladder cancer	1.67e-05	0.000142	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—ERBB2—gallbladder cancer	1.66e-05	0.000141	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—KRAS—gallbladder cancer	1.66e-05	0.000141	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—NRAS—gallbladder cancer	1.64e-05	0.00014	CbGpPWpGaD
Afatinib—ERBB4—Disease—EGFR—gallbladder cancer	1.64e-05	0.00014	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—gallbladder cancer	1.64e-05	0.000139	CbGpPWpGaD
Afatinib—BLK—Immune System—KRAS—gallbladder cancer	1.62e-05	0.000138	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—KRAS—gallbladder cancer	1.6e-05	0.000137	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—HRAS—gallbladder cancer	1.59e-05	0.000136	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—NRAS—gallbladder cancer	1.59e-05	0.000135	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—NRAS—gallbladder cancer	1.58e-05	0.000135	CbGpPWpGaD
Afatinib—ERBB2—Disease—KRAS—gallbladder cancer	1.57e-05	0.000134	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—HRAS—gallbladder cancer	1.56e-05	0.000133	CbGpPWpGaD
Afatinib—ERBB4—Disease—KRAS—gallbladder cancer	1.55e-05	0.000132	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	1.54e-05	0.000131	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—NRAS—gallbladder cancer	1.52e-05	0.00013	CbGpPWpGaD
Afatinib—ABL1—Immune System—BCL2—gallbladder cancer	1.52e-05	0.000129	CbGpPWpGaD
Afatinib—LCK—Hemostasis—KRAS—gallbladder cancer	1.52e-05	0.000129	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ERBB4—gallbladder cancer	1.5e-05	0.000128	CbGpPWpGaD
Afatinib—ABL1—Immune System—ERBB2—gallbladder cancer	1.47e-05	0.000126	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HRAS—gallbladder cancer	1.45e-05	0.000123	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ERBB4—gallbladder cancer	1.45e-05	0.000123	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—EGFR—gallbladder cancer	1.44e-05	0.000123	CbGpPWpGaD
Afatinib—IRAK1—Immune System—NRAS—gallbladder cancer	1.43e-05	0.000122	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HRAS—gallbladder cancer	1.43e-05	0.000122	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—KRAS—gallbladder cancer	1.42e-05	0.000121	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HRAS—gallbladder cancer	1.41e-05	0.00012	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—EGFR—gallbladder cancer	1.39e-05	0.000118	CbGpPWpGaD
Afatinib—BLK—Immune System—HRAS—gallbladder cancer	1.37e-05	0.000117	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—KRAS—gallbladder cancer	1.36e-05	0.000116	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—HRAS—gallbladder cancer	1.36e-05	0.000116	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—KRAS—gallbladder cancer	1.36e-05	0.000116	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—gallbladder cancer	1.35e-05	0.000115	CbGpPWpGaD
Afatinib—ERBB2—Disease—HRAS—gallbladder cancer	1.34e-05	0.000114	CbGpPWpGaD
Afatinib—ERBB4—Disease—HRAS—gallbladder cancer	1.32e-05	0.000112	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—KRAS—gallbladder cancer	1.31e-05	0.000112	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EGFR—gallbladder cancer	1.31e-05	0.000111	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ERBB3—gallbladder cancer	1.3e-05	0.000111	CbGpPWpGaD
Afatinib—EGFR—Immune System—BCL2—gallbladder cancer	1.3e-05	0.00011	CbGpPWpGaD
Afatinib—LCK—Hemostasis—HRAS—gallbladder cancer	1.29e-05	0.00011	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NRAS—gallbladder cancer	1.28e-05	0.000109	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NRAS—gallbladder cancer	1.26e-05	0.000107	CbGpPWpGaD
Afatinib—EGFR—Immune System—ERBB2—gallbladder cancer	1.26e-05	0.000107	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ERBB3—gallbladder cancer	1.25e-05	0.000107	CbGpPWpGaD
Afatinib—LCK—Immune System—BCL2—gallbladder cancer	1.25e-05	0.000106	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KRAS—gallbladder cancer	1.23e-05	0.000105	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ERBB2—gallbladder cancer	1.22e-05	0.000104	CbGpPWpGaD
Afatinib—LCK—Immune System—ERBB2—gallbladder cancer	1.21e-05	0.000103	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HRAS—gallbladder cancer	1.2e-05	0.000102	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—gallbladder cancer	1.17e-05	9.94e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—ERBB2—gallbladder cancer	1.16e-05	9.9e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HRAS—gallbladder cancer	1.16e-05	9.88e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HRAS—gallbladder cancer	1.16e-05	9.84e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—gallbladder cancer	1.15e-05	9.79e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—NRAS—gallbladder cancer	1.12e-05	9.55e-05	CbGpPWpGaD
Afatinib—LCK—Disease—ERBB2—gallbladder cancer	1.12e-05	9.54e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—gallbladder cancer	1.11e-05	9.49e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KRAS—gallbladder cancer	1.1e-05	9.39e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KRAS—gallbladder cancer	1.09e-05	9.25e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—NRAS—gallbladder cancer	1.05e-05	8.93e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—gallbladder cancer	1.05e-05	8.93e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—gallbladder cancer	1.02e-05	8.7e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—gallbladder cancer	9.8e-06	8.35e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—gallbladder cancer	9.65e-06	8.22e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—KRAS—gallbladder cancer	9.65e-06	8.22e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—NRAS—gallbladder cancer	9.58e-06	8.16e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—gallbladder cancer	9.37e-06	7.98e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NRAS—gallbladder cancer	9.26e-06	7.89e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—gallbladder cancer	9.23e-06	7.86e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NRAS—gallbladder cancer	9.23e-06	7.86e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KRAS—gallbladder cancer	9.02e-06	7.69e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NRAS—gallbladder cancer	8.85e-06	7.53e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NRAS—gallbladder cancer	8.52e-06	7.26e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—gallbladder cancer	8.44e-06	7.19e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—gallbladder cancer	8.41e-06	7.16e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—KRAS—gallbladder cancer	8.25e-06	7.02e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—gallbladder cancer	8.2e-06	6.99e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ERBB2—gallbladder cancer	8.14e-06	6.93e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KRAS—gallbladder cancer	7.97e-06	6.79e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—KRAS—gallbladder cancer	7.95e-06	6.77e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ERBB2—gallbladder cancer	7.85e-06	6.68e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—gallbladder cancer	7.77e-06	6.61e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—gallbladder cancer	7.67e-06	6.53e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—KRAS—gallbladder cancer	7.61e-06	6.48e-05	CbGpPWpGaD
Afatinib—LCK—Disease—KRAS—gallbladder cancer	7.34e-06	6.25e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—gallbladder cancer	7.09e-06	6.04e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—gallbladder cancer	7.01e-06	5.97e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—gallbladder cancer	6.78e-06	5.77e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—gallbladder cancer	6.75e-06	5.75e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—gallbladder cancer	6.47e-06	5.51e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—gallbladder cancer	6.24e-06	5.31e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NRAS—gallbladder cancer	6.19e-06	5.28e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NRAS—gallbladder cancer	5.97e-06	5.08e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—gallbladder cancer	5.44e-06	4.63e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KRAS—gallbladder cancer	5.33e-06	4.54e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KRAS—gallbladder cancer	5.14e-06	4.38e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—gallbladder cancer	4.74e-06	4.04e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—gallbladder cancer	4.57e-06	3.89e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—gallbladder cancer	4.53e-06	3.86e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—gallbladder cancer	4.37e-06	3.72e-05	CbGpPWpGaD
